Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advanced Therapies

This article was originally published in SRA

Executive Summary

Work on proposal continues

Work on proposal continues

The European Commission is working on an impact assessment detailing how comments on its recent proposed framework for the regulation of advanced therapies have been taken into account1. The proposal, which was released on 4 May 2005, puts forward an approach to establish a single regulatory mechanism for all advanced therapy products, including human tissue-engineered products, within the EU. Comments received will be published on the commission website shortly. The proposal is part of the Commission Legislative and Work Programme for 2005 and is on track to be formally adopted by the commission and officially published in November 2005. It will then be forwarded to the council and European parliament.

References

1. Personal communication, European Commission, 26 September 2005

Latest Headlines
See All
UsernamePublicRestriction

Register

PS110875

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel